tetano
Editor, Senior Moderator
SAGE Open Med Case Rep
. 2021 Feb 23;9:2050313X21997194.
doi: 10.1177/2050313X21997194. eCollection 2021.
Cutaneous manifestations of COVID-19 in Mexican patients: A case series and review of literature
Juan Carlos Palomo-P?rez[SUP] 1 2 [/SUP], Maria Elisa Vega-Memije[SUP] 3 [/SUP], David Aguilar-Blancas[SUP] 4 [/SUP], Erik Gonz?lez-Mart?nez[SUP] 5 [/SUP], Lucia Rangel-Gamboa[SUP] 5 6 [/SUP]
Affiliations
Abstract
China officially recognized atypical pneumonia outbreak in December 2019; on 11 March 2020, the World Health Organization declared COVID-19 as a pandemic that is produced by a new coronavirus, named SARS-CoV-2, of rapid transmissibility, which can be asymptomatic, with mild to severe respiratory symptoms, and with cardiovascular, neurological, gastrointestinal, and cutaneous complications. Considering that the pandemic prolonged more than initially expected was prognostic, it is essential for the medical community to identify the signs and symptoms of COVID-19. Thus, this work's objectives were to present cases of cutaneous lesions observed in COVID-19 Mexican patients. We register cutaneous lesions in COVID-19 patients referred from internal medicine and otorhinolaryngology services to dermatology. We presented four interesting cases with cutaneous lesions, including exanthema morbilliform, urticaria, chilblains, ecchymosis, and facial edema, and review the available literature. The most frequent cutaneous markers are rash, chilblains, and urticaria. Skin lesions may be the first manifestation of COVID-19, accompany initial respiratory symptoms, or appear during the disease course. Symptoms associated with vascular changes (livedo reticularis and vasculitis) are considered of poor prognosis.
Keywords: COVID-19; SARS-CoV-2; chilblain; livedo reticularis; rash; urticaria; vasculitis.
. 2021 Feb 23;9:2050313X21997194.
doi: 10.1177/2050313X21997194. eCollection 2021.
Cutaneous manifestations of COVID-19 in Mexican patients: A case series and review of literature
Juan Carlos Palomo-P?rez[SUP] 1 2 [/SUP], Maria Elisa Vega-Memije[SUP] 3 [/SUP], David Aguilar-Blancas[SUP] 4 [/SUP], Erik Gonz?lez-Mart?nez[SUP] 5 [/SUP], Lucia Rangel-Gamboa[SUP] 5 6 [/SUP]
Affiliations
- PMID: 33747514
- PMCID: PMC7905726
- DOI: 10.1177/2050313X21997194
Abstract
China officially recognized atypical pneumonia outbreak in December 2019; on 11 March 2020, the World Health Organization declared COVID-19 as a pandemic that is produced by a new coronavirus, named SARS-CoV-2, of rapid transmissibility, which can be asymptomatic, with mild to severe respiratory symptoms, and with cardiovascular, neurological, gastrointestinal, and cutaneous complications. Considering that the pandemic prolonged more than initially expected was prognostic, it is essential for the medical community to identify the signs and symptoms of COVID-19. Thus, this work's objectives were to present cases of cutaneous lesions observed in COVID-19 Mexican patients. We register cutaneous lesions in COVID-19 patients referred from internal medicine and otorhinolaryngology services to dermatology. We presented four interesting cases with cutaneous lesions, including exanthema morbilliform, urticaria, chilblains, ecchymosis, and facial edema, and review the available literature. The most frequent cutaneous markers are rash, chilblains, and urticaria. Skin lesions may be the first manifestation of COVID-19, accompany initial respiratory symptoms, or appear during the disease course. Symptoms associated with vascular changes (livedo reticularis and vasculitis) are considered of poor prognosis.
Keywords: COVID-19; SARS-CoV-2; chilblain; livedo reticularis; rash; urticaria; vasculitis.